NIKKEI 225
27,462.80 +77.55 (+0.28%) HANG SENG
19,587.94 -327.74 (-1.65%) CRUDE OIL
69.15 -0.11 (-0.16%) GOLD FUTURES
1,975.70 -8.10 (-0.41%) DOW
32,237.53 +132.33 (+0.41%) BTC-GBP
22,747.70 +177.13 (+0.78%)
FOXO Technologies Inc. (FOXO)
After hours:
| Previous close | 0.3336 |
| Open | 0.3336 |
| Bid | 0.3330 x 1400 |
| Ask | 0.3550 x 900 |
| Day's range | 0.3072 - 0.3673 |
| 52-week range | 0.2300 - 7.2900 |
| Volume | |
| Avg. volume | 2,992,463 |
| Market cap | 11.227M |
| Beta (5Y monthly) | 2.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 21 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
FOXO Technologies Inc. Sets Fourth Quarter and Full Year 2022 Business Update Call for Thursday, March 30, 2023 at 3:15 p.m. CT
MINNEAPOLIS, March 22, 2023--FOXO Technologies Inc. (NYSE_AM: FOXO), a leader in commercializing epigenetic biomarkers of health and aging, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022 after market closes on Thursday, March 30, 2023.
- Business Wire
FOXO LIFE™ to Begin Distribution Relationship with AmSuisse to Sell Life Insurance Designed to Keep You Alive™
MINNEAPOLIS, December 08, 2022--FOXO Technologies Inc.™ (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that its insurance distribution subsidiary, FOXO LIFE™, has engaged AmSuisse, an insurance brokerage general agency with products and specialty programs throughout the United States, to sell Life Insurance Designed to Keep You Alive™.
- Business Wire
FOXO Technologies Announces Filing of Form 10-Q for the Third Quarter 2022
MINNEAPOLIS, November 23, 2022--FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that the Company has filed its Form 10-Q for the third quarter ended September 30, 2022.
